Milestone Pharmaceuticals Inc. (MIST) stock
MISTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.52−0.14 (-20.63%)
Close on Nov 13, 2026Market cap $64.74MP/E –Yield –
Milestone Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Milestone Pharmaceuticals's total assets was $162.70M at Sep 30, 2026. For fiscal 2025 it was $113.56M, up 50.4% from the year before. The highest annual figure on record is $149.97M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.56M | +50.4% |
| FY2024 | Dec 31, 2024 | $75.50M | +0.4% |
| FY2023 | Dec 31, 2023 | $75.23M | +1.0% |
| FY2022 | Dec 31, 2022 | $74.48M | -37.9% |
| FY2021 | Dec 31, 2021 | $119.85M | -20.1% |
| FY2020 | Dec 31, 2020 | $149.97M | +21.5% |
| FY2019 | Dec 31, 2019 | $123.43M | +40.1% |
| FY2018 | Dec 31, 2018 | $88.08M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $162.70M | +85.4% |
| Q2 FY2026 | Jun 30, 2026 | $181.63M | +283.0% |
| Q1 FY2026 | Mar 31, 2026 | $193.73M | +213.1% |
| Q4 FY2025 | Dec 31, 2025 | $113.56M | +50.4% |
| Q3 FY2025 | Sep 30, 2025 | $87.75M | +6.1% |
| Q2 FY2025 | Jun 30, 2025 | $47.42M | -46.9% |
| Q1 FY2025 | Mar 31, 2025 | $61.89M | -35.5% |
| Q4 FY2024 | Dec 31, 2024 | $75.50M | +0.4% |
| Q3 FY2024 | Sep 30, 2024 | $82.71M | -5.1% |
| Q2 FY2024 | Jun 30, 2024 | $89.23M | -8.0% |
| Q1 FY2024 | Mar 31, 2024 | $96.00M | -13.6% |
| Q4 FY2023 | Dec 31, 2023 | $75.23M | +1.0% |
| Q3 FY2023 | Sep 30, 2023 | $87.12M | +1.6% |
| Q2 FY2023 | Jun 30, 2023 | $97.02M | +6.3% |
| Q1 FY2023 | Mar 31, 2023 | $111.08M | +5.0% |
| Q4 FY2022 | Dec 31, 2022 | $74.48M | -37.9% |
| Q3 FY2022 | Sep 30, 2022 | $85.77M | -35.9% |
| Q2 FY2022 | Jun 30, 2022 | $91.30M | -37.2% |
| Q1 FY2022 | Mar 31, 2022 | $105.80M | -23.6% |
| Q4 FY2021 | Dec 31, 2021 | $119.85M | -20.1% |
| Q3 FY2021 | Sep 30, 2021 | $133.78M | +23.0% |
| Q2 FY2021 | Jun 30, 2021 | $145.50M | +56.2% |
| Q1 FY2021 | Mar 31, 2021 | $138.44M | +31.7% |
| Q4 FY2020 | Dec 31, 2020 | $149.97M | +21.5% |
| Q3 FY2020 | Sep 30, 2020 | $108.80M | -23.3% |
| Q2 FY2020 | Jun 30, 2020 | $93.14M | -38.7% |
| Q1 FY2020 | Mar 31, 2020 | $105.16M | +35.5% |
| Q4 FY2019 | Dec 31, 2019 | $123.43M | +40.1% |
| Q3 FY2019 | Sep 30, 2019 | $141.89M | – |
| Q2 FY2019 | Jun 30, 2019 | $151.84M | – |
| Q1 FY2019 | Mar 31, 2019 | $77.59M | – |
| Q4 FY2018 | Dec 31, 2018 | $88.08M | – |
See a number that looks wrong?